Eli Lilly announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion for Emgality for the prophylaxis of migraine in adults who have at least four migraine days per month. In June 2018, Lilly announced the intended brand name, Emgality, was conditionally accepted by the U.S. FDA.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.